Frankfurt - Delayed Quote EUR

Blueprint Medicines Corporation (2L9.F)

110.00
-0.95
(-0.86%)
At close: June 12 at 9:12:02 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
562,121
508,824
249,380
204,036
180,080
Cost of Revenue
19,774
20,163
8,540
17,813
17,934
Gross Profit
542,347
488,661
240,840
186,223
162,146
Operating Expense
716,654
700,705
722,861
714,793
796,326
Operating Income
-174,307
-212,044
-482,021
-528,570
-634,180
Net Non Operating Interest Income Expense
-30,385
-28,151
-18,793
-16,767
2,386
Other Income Expense
50,798
174,332
-5,202
-6,944
-9,290
Pretax Income
-153,894
-65,863
-506,016
-552,281
-641,084
Tax Provision
1,835
1,226
968
5,236
3,001
Net Income Common Stockholders
-155,729
-67,089
-506,984
-557,517
-644,085
Diluted NI Available to Com Stockholders
-155,729
-67,089
-506,984
-557,517
-644,085
Basic EPS
-2.51
-1.07
-8.37
-9.35
-11.01
Diluted EPS
-2.51
-1.07
-8.37
-9.35
-11.01
Basic Average Shares
63,486
62,857
60,558
59,642
58,518
Diluted Average Shares
63,538
62,857
60,558
59,642
58,518
Total Expenses
736,428
720,868
731,401
732,606
814,260
Net Income from Continuing & Discontinued Operation
-155,729
-67,089
-506,984
-557,517
-644,085
Normalized Income
-155,739.80
-204,293.04
-506,984
-557,517
-644,085
Interest Income
41,154
40,655
32,812
--
--
Interest Expense
71,539
68,806
51,605
--
--
Net Interest Income
-30,385
-28,151
-18,793
-16,767
2,386
EBIT
-82,355
2,943
-454,411
-528,570
-634,180
EBITDA
-66,415
19,234
-442,746
-516,835
-627,701
Reconciled Cost of Revenue
19,774
20,163
8,540
17,813
17,934
Reconciled Depreciation
15,940
16,291
11,665
11,735
6,479
Net Income from Continuing Operation Net Minority Interest
-155,729
-67,089
-506,984
-557,517
-644,085
Total Unusual Items Excluding Goodwill
18
173,676
0
0
--
Total Unusual Items
18
173,676
0
0
--
Normalized EBITDA
-66,433
-154,442
-442,746
-516,835
-627,701
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
7.20
36,471.96
0
0
0
12/31/2021 - 5/11/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

UP0.F Ultragenyx Pharmaceutical Inc.
32.20
-1.23%
 
38I.F Intellia Therapeutics, Inc.
7.50
-2.60%
 
4DN.MU Denali Therapeutics Inc.
13.20
0.00%
 
26CA.F ImmunityBio, Inc.
2.7330
-2.43%
 
2LB.F Iovance Biotherapeutics, Inc.
1.9094
-9.05%
 
NEXI NexImmune, Inc.
0.0001
0.00%
 
LVTX LAVA Therapeutics N.V.
1.3100
-2.24%
 
IKNA Ikena Oncology, Inc.
1.3700
-2.84%
 
OVID Ovid Therapeutics Inc.
0.2893
-9.25%
 
TLX Telix Pharmaceuticals Limited
17.46
+1.90%